Business Context and Reporting Period
This Form 6-K filing by Evaxion Biotech A/S covers the month of January 2025, with the report dated January 7, 2025. The filing primarily addresses a corporate action involving an amendment to the Company's Articles of Association following a registered share capital increase.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes rather than operational financial performance.
- Share Capital Increase: Aggregate nominal increase of DKK 11,470,000.
- Total Share Capital: Increased to nominal DKK 70,130,556.
- Transaction Type: Exercise of pre-funded warrants.
- Exercise Price: $1.4537 per American Depositary Share (ADS).
- ADS Conversion: Each ADS represents ten (10) ordinary shares.
Material Changes
The material change reported is the increase in registered share capital effective December 26 and December 27, 2024. This change resulted from the exercise of pre-funded warrants, leading to an amendment of the Articles of Association to reflect the new capital structure.
Outlook, Risks, and Unusual Items
The filing does not contain management commentary on future guidance, outlook, or specific risks. It notes that remaining pre-funded warrants confer the right to subscribe to 851,000 ADSs at the same exercise price of $1.4537 per Warrant ADS.
Investor Verification Checklist
- Verify the total number of ordinary shares issued following the DKK 11,470,000 capital increase.
- Confirm the dilution impact of the remaining 851,000 pre-funded warrants exercisable at $1.4537 per ADS.
- Review the attached Exhibit 1.1 (Articles of Association) for updated governance terms.
- Check subsequent filings for the cash proceeds generated from the warrant exercises, as this filing does not explicitly state the cash inflow amount.